BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 8:39:00 PM | Browse: 515 | Download: 502
Publication Name World Journal of Gastroenterology
Manuscript ID 5557
Country of Manuscript Source Greece
2013-09-15 20:29
Peer-Review Started
2013-09-16 10:45
To Make the First Decision
2013-10-14 21:21
Return for Revision
2013-10-15 20:00
2013-10-29 15:42
Second Decision
2013-11-18 20:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-11-19 11:58
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-11-27 00:22
Typeset the Manuscript
2013-12-16 11:55
Publish the Manuscript Online
2014-01-14 20:11
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Topic Highlights
Article Title Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation
Manuscript Source Invited Manuscript
All Author List Evangelos Cholongitas and George V Papatheodoridis
Funding Agency and Grant Number
Corresponding author Dr. Evangelos Cholongitas, Lecturer of Internal Medicine, the 4th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, 49, Konstantinopoleos Street, 54642 Thessaloniki, Greece. cholongitas@yahoo.gr
Keywords Hepatitis B virus; Liver transplantation; Hepatitis B virus immunoglobulin; Antivirals; Lamivudine; Adefovir; Entecavir; Tenofovir; Telbivudine; Resistance
Core Tip In the present review the current knowledge on the management of hepatitis B virus (HBV) infection before and after liver transplantation is updated. There is no doubt that all HBV patients with decompensated cirrhosis should be treated with potent anti-HBV agents with high genetic barrier (i.e., entecavir or tenofovir). After liver transplantation, the combination of HBV immunoglobulin (HBIG) (at least for a certain period) and entecavir or tenofovir currently appears to be the most reasonable approach, while HBIG-free antiviral prophylaxis cannot be excluded in the future, particularly in patients with low risk of recurrence.
Publish Date 2014-01-14 20:11
Citation Cholongitas E, Papatheodoridis GV. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol 2013; 19(48): 9189-9197
Url http://www.wjgnet.com/1007-9327/full/v19/i48/9189.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i48.9189
Full Article (PDF) WJG-19-9189.pdf
Manuscript File 5557-Review.doc
Answering Reviewers 5557-Answering reviews.pdf
Copyright License Agreement 5557-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 5557-Language certificate.pdf
Peer-review Report 5557-Peer review(s).pdf
Scientific Editor Work List 5557-Scientific editor work list.doc